JPWO2022015736A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022015736A5 JPWO2022015736A5 JP2023501802A JP2023501802A JPWO2022015736A5 JP WO2022015736 A5 JPWO2022015736 A5 JP WO2022015736A5 JP 2023501802 A JP2023501802 A JP 2023501802A JP 2023501802 A JP2023501802 A JP 2023501802A JP WO2022015736 A5 JPWO2022015736 A5 JP WO2022015736A5
- Authority
- JP
- Japan
- Prior art keywords
- raf
- antibody
- inhibitor
- mek
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 73
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 38
- 229940125436 dual inhibitor Drugs 0.000 claims description 31
- 229940124783 FAK inhibitor Drugs 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 6
- 229940124647 MEK inhibitor Drugs 0.000 claims description 5
- 230000009977 dual effect Effects 0.000 claims description 5
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 5
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 4
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 4
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 4
- 229940121514 toripalimab Drugs 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000005431 Endometrioid Carcinoma Diseases 0.000 claims description 2
- 102100029974 GTPase HRas Human genes 0.000 claims description 2
- 102100030708 GTPase KRas Human genes 0.000 claims description 2
- 102100039788 GTPase NRas Human genes 0.000 claims description 2
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035603 Pleural mesothelioma Diseases 0.000 claims description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 2
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims description 2
- 201000005969 Uveal melanoma Diseases 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 229950002916 avelumab Drugs 0.000 claims description 2
- 229940121530 balstilimab Drugs 0.000 claims description 2
- 230000002051 biphasic effect Effects 0.000 claims description 2
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims description 2
- 201000001528 bladder urothelial carcinoma Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 229950007712 camrelizumab Drugs 0.000 claims description 2
- 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 claims description 2
- 229940121420 cemiplimab Drugs 0.000 claims description 2
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 2
- 229950008937 defactinib Drugs 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 201000003683 endocervical adenocarcinoma Diseases 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 208000028730 endometrioid adenocarcinoma Diseases 0.000 claims description 2
- 229940066764 geptanolimab Drugs 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- FWLMVFUGMHIOAA-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical group C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 FWLMVFUGMHIOAA-UHFFFAOYSA-N 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 229950010773 pidilizumab Drugs 0.000 claims description 2
- 102000016914 ras Proteins Human genes 0.000 claims description 2
- 229940018007 retifanlimab Drugs 0.000 claims description 2
- 229940018073 sasanlimab Drugs 0.000 claims description 2
- 229940121497 sintilimab Drugs 0.000 claims description 2
- 201000003708 skin melanoma Diseases 0.000 claims description 2
- 229940125310 socazolimab Drugs 0.000 claims description 2
- 229950007213 spartalizumab Drugs 0.000 claims description 2
- 229940062046 sugemalimab Drugs 0.000 claims description 2
- 229940061918 tebotelimab Drugs 0.000 claims description 2
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 229940052007 zimberelimab Drugs 0.000 claims 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051320P | 2020-07-13 | 2020-07-13 | |
| US63/051,320 | 2020-07-13 | ||
| PCT/US2021/041439 WO2022015736A1 (en) | 2020-07-13 | 2021-07-13 | Combination therapy for treating abnormal cell growth |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023534009A JP2023534009A (ja) | 2023-08-07 |
| JP2023534009A5 JP2023534009A5 (https=) | 2024-07-23 |
| JPWO2022015736A5 true JPWO2022015736A5 (https=) | 2024-07-23 |
Family
ID=79554253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501802A Pending JP2023534009A (ja) | 2020-07-13 | 2021-07-13 | 異常な細胞成長を処置するための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230330088A1 (https=) |
| EP (1) | EP4178573A4 (https=) |
| JP (1) | JP2023534009A (https=) |
| KR (1) | KR20230039684A (https=) |
| CN (1) | CN116056699A (https=) |
| AU (1) | AU2021307410A1 (https=) |
| BR (1) | BR112023000675A2 (https=) |
| CA (1) | CA3189383A1 (https=) |
| IL (1) | IL299789A (https=) |
| MX (1) | MX2023000589A (https=) |
| WO (1) | WO2022015736A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7582694B2 (ja) | 2020-01-10 | 2024-11-13 | イミューニヤリング コーポレーション | Ｍｅｋ阻害剤及びその治療的使用 |
| TW202329967A (zh) * | 2022-01-21 | 2023-08-01 | 大陸商應世生物科技（南京）有限公司 | 治療腫瘤的藥物組合及用途 |
| CN116120461B (zh) * | 2022-04-29 | 2023-09-29 | 德琪(杭州)生物有限公司 | 新型抗药抗体以及其用途 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| CN119947725A (zh) * | 2022-09-30 | 2025-05-06 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
| WO2024178274A2 (en) * | 2023-02-24 | 2024-08-29 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods of degrading raf(raf) protein in cells using mitogen-activated protein kinase kinase 1/2 (mek1/2) protein degraders |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025079712A1 (ja) * | 2023-10-12 | 2025-04-17 | 中外製薬株式会社 | ドライバー変異を有するがん患者における分子標的薬併用療法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6238459B2 (ja) * | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| US20170112865A1 (en) * | 2014-05-21 | 2017-04-27 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| SG11201700074YA (en) * | 2014-07-15 | 2017-02-27 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| JP2018519327A (ja) * | 2015-06-29 | 2018-07-19 | ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． | 治療用組成物、組合せ物および使用の方法 |
| CN109663130B (zh) * | 2017-10-13 | 2021-06-29 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 |
| WO2021047783A1 (en) * | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
-
2021
- 2021-07-13 AU AU2021307410A patent/AU2021307410A1/en active Pending
- 2021-07-13 MX MX2023000589A patent/MX2023000589A/es unknown
- 2021-07-13 CN CN202180049487.0A patent/CN116056699A/zh active Pending
- 2021-07-13 WO PCT/US2021/041439 patent/WO2022015736A1/en not_active Ceased
- 2021-07-13 BR BR112023000675A patent/BR112023000675A2/pt unknown
- 2021-07-13 JP JP2023501802A patent/JP2023534009A/ja active Pending
- 2021-07-13 US US18/005,012 patent/US20230330088A1/en active Pending
- 2021-07-13 KR KR1020237004543A patent/KR20230039684A/ko active Pending
- 2021-07-13 EP EP21841921.6A patent/EP4178573A4/en active Pending
- 2021-07-13 CA CA3189383A patent/CA3189383A1/en active Pending
- 2021-07-13 IL IL299789A patent/IL299789A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022015736A5 (https=) | ||
| EP4337191B1 (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| Gbolahan et al. | A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma | |
| Ducreux et al. | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study) | |
| JP2025020147A5 (https=) | ||
| JPWO2021154929A5 (https=) | ||
| TW200412937A (en) | Combination chemotherapy | |
| US12213958B2 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| JP2023542093A (ja) | 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 | |
| WO2011061222A1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| JPWO2022270524A5 (https=) | ||
| Kimura et al. | Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy | |
| JP6359198B1 (ja) | がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤 | |
| JPWO2023009572A5 (https=) | ||
| JP2021063014A (ja) | 白血病治療薬 | |
| JPWO2019196764A5 (https=) | ||
| JP6023902B1 (ja) | 高齢又は末期の癌患者を治療又は寛解するための医薬組成物 | |
| CN116115623B (zh) | 2'-岩藻糖基乳糖作为一种抗肿瘤辅助药物的应用 | |
| CN107349426B (zh) | 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用 | |
| Mizushima et al. | A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer | |
| Jones et al. | A randomized phase II trial of oral Topotecan versus Docetaxel in the second-line treatment of non–small-cell lung cancer | |
| CN115135326A (zh) | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 | |
| CN112870365A (zh) | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 | |
| Yeo et al. | Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors | |
| Trafalis et al. | Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: from bench to bedside? |